期刊文献+

阿托伐他丁对2型糖尿病颈内动脉内 ̄中膜增厚的干预研究 被引量:1

Intervention Study of Atorvastatin for Carotid Artery Intima-media Thickness of Type 2 Diabetes
下载PDF
导出
摘要 目的观察阿托伐他丁对2型糖尿病颈内动脉内-中膜增厚的影响,探讨阿托伐他丁在2型糖尿病治疗中的作用。方法从收治的2型糖尿病患者中选取颈动脉轻中度增厚的120例,随机分为阿托伐他汀治疗组和对照组,每组60例。对照组在控制饮食、健康锻炼的基础上予以降血糖治疗,治疗组在对照组的基础上给予口服阿托伐他汀治疗。结果经过严格治疗6个月后,治疗组患者颈内-中膜的厚度较治疗前显著降低,差异有统计学意义(P<0.05)。对照组患者颈内-中膜的厚度较治疗前无明显变化,差异无统计学意义(P>0.05)。结论阿托伐他丁对2型糖尿病颈内动脉内-中膜增厚的干预效果明显,能降低颈内动脉内-中膜厚度,稳定并逆转粥样斑块,具有良好的临床价值。 Objective To evaluate the influence the effect of atorvastatin for carotid artery intima-media thickness of type 2 diabetes. Methods 120 patients from march 2011 to November 2012 who were diagnosed with type 2 diabetes as well as carotid artery intima-media thickness were selected,and randomly divided into atorvastatin treatment group(60 patients) and control group(60 patients). All the patients were on diet and took exercise as hypoglycemic therapy. The patients in atorvastatin treatment group use atorvastatin. Results Compared with before treatment, intima-media thickness in atorvastatin treatment group was improved significantly(P0.05), the difference was statistically significant. While intima-media thickness in control group was similar(P0.05) with before treatment, the difference was not statistically significant.Conclusion The efficacy of atorvastatin on carotid intima-media thickness in patients with type 2 diabetes is significantly, it is much more valuable for patients with type 2 diabetes.
作者 班春梅
出处 《现代诊断与治疗》 CAS 2013年第13期2886-2888,共3页 Modern Diagnosis and Treatment
关键词 阿托伐他丁 2型糖尿病 颈内动脉 内-中膜增厚 Atorvastatin Type 2 Diabetes Carotid Artery Intima-media Thickness
  • 相关文献

参考文献4

二级参考文献41

  • 1于建刚,钱建东,徐红,袁雪芬,徐丽芳,朱建琴.阿托伐他汀钙对脑梗死患者颈动脉斑块影响的临床研究[J].华西医学,2008,23(6):1305-1306. 被引量:14
  • 2邸晓辉,杨永革,梅巍,刘静,许雪廷.阿托伐他汀钙胶囊的人体生物等效性研究[J].解放军药学学报,2005,21(4):262-265. 被引量:8
  • 3MARITIM AC, SANDERS RA,WAT KINS JB. Diabetes, oxidative stress and antioxidants [ J ]. Biochem Mol Toxicol, 2003,17 (1) :24 -38.
  • 4GRAWEL S,WARDAS M, WOROKE N,et al. Malondialdehyde (MDA) as a lipid peroxidation marker[ J]. Wiad Lek,2004,57 (9 - 10) :453 -455.
  • 5SONG YB,ON YK, KIM JH,et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off2pump coronary artery bypass grafting surgery [ J ]. Am Heart J, 2008, 156(2) :9 -16.
  • 6TSAI CT,LAI LP,HWANG JJ,et al. Atorvastatin prevents atrial fibrillation in patients with bradyar rhythm ias and implantation of an atrial-based or dual-chain-bet pacemaker: a prospective randomized trial [ J ]. Am Heart J, 2008,156 ( 1 ) : 65 - 70.
  • 7GILLIS AM,MORCK M,EXNER DV,et al. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker imp lantation [ J ]. Eur Heart J, 2008,29 ( 15 ) : 1873 - 1880.
  • 8LEE SH,CHUNG N,KWAN J,et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin : an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia [ J ]. Clin Ther, 2007,29 ( 11 ) :2365 -2373.
  • 9YOSHITOMI Y, ISHII T, KANEKI M,et al. Efficacy of a low dose of pitavastatin compared with atorvaststin in primary hyperlipidemia : result of a 12-week, open label study [ J ]. J Atheroscler Thromb ,2006,13 ( 2 ) : 108 - 113.
  • 10Grunt SM,Benjamin CI,Burke GL,et al.Diabetes and cardiovascular disease[J].Circulation,1999,100:1134.

共引文献119

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部